A Nature Biotechnology paper reported that antimicrobial peptides encoded as mRNA 'peptibodies' and delivered to mouse lungs in anti‑inflammatory lipid formulations eradicated multidrug‑resistant bacterial pneumonia in preclinical models. The approach couples sequence‑encoded AMPs with lipid nanoparticles optimized for pulmonary delivery and inflammation modulation to enhance efficacy while limiting host damage. Authors argue the strategy could widen the therapeutic toolbox against resistant respiratory pathogens and reduce selective pressure for classic antibiotics. Findings are preclinical; translation will require dosing, safety and manufacturability studies, and evaluation of immunogenicity in larger animal models and humans.